George A - Search Results

1

A Cost-Effectiveness Evaluation of Germline BRCA1 and BRCA2 Testing in UK Women with Ovarian Cancer.

Eccleston A, Bentley A, Dyer M, Strydom A, Vereecken W, George A, Rahman N. Eccleston A, et al. Among authors: george a. Value Health. 2017 Apr;20(4):567-576. doi: 10.1016/j.jval.2017.01.004. Epub 2017 Mar 3. Value Health. 2017. PMID: 28407998 Free PMC article.

2

UK BRCA mutation testing in patients with ovarian cancer.

George A. George A. Br J Cancer. 2015 Dec 15;113 Suppl 1(Suppl 1):S17-21. doi: 10.1038/bjc.2015.396. Br J Cancer. 2015. PMID: 26669451 Free PMC article. Review.

3

A cost analysis of a cancer genetic service model in the UK.

Slade I, Hanson H, George A, Kohut K, Strydom A, Wordsworth S, Rahman N; MCG programme. Slade I, et al. Among authors: george a. J Community Genet. 2016 Jul;7(3):185-94. doi: 10.1007/s12687-016-0266-4. Epub 2016 Feb 27. J Community Genet. 2016. PMID: 26922077 Free PMC article.

4

BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.

Moschetta M, George A, Kaye SB, Banerjee S. Moschetta M, et al. Among authors: george a. Ann Oncol. 2016 Aug;27(8):1449-55. doi: 10.1093/annonc/mdw142. Epub 2016 Mar 31. Ann Oncol. 2016. PMID: 27037296 Free article. Review.

5

Cost-Effectiveness Analysis of Testing for Brca Mutations in Women Diagnosed with Ovarian Cancer and their Female First-Degree Relatives: A Uk Health Service Perspective.

Dyer M, Vereecken W, Worrall J, George A, Rahman N. Dyer M, et al. Among authors: george a. Value Health. 2014 Nov;17(7):A643-4. doi: 10.1016/j.jval.2014.08.2327. Epub 2014 Oct 26. Value Health. 2014. PMID: 27202307 Free article. No abstract available.

6

The integration of BRCA testing into oncology clinics.

Percival N, George A, Gyertson J, Hamill M, Fernandes A, Davies E, Rahman N, Banerjee S. Percival N, et al. Among authors: george a. Br J Nurs. 2016 Jun 23;25(12):690-4. doi: 10.12968/bjon.2016.25.12.690. Br J Nurs. 2016. PMID: 27345073 Free PMC article.

7

Implementing rapid, robust, cost-effective, patient-centred, routine genetic testing in ovarian cancer patients.

George A, Riddell D, Seal S, Talukdar S, Mahamdallie S, Ruark E, Cloke V, Slade I, Kemp Z, Gore M, Strydom A, Banerjee S, Hanson H, Rahman N. George A, et al. Sci Rep. 2016 Jul 13;6:29506. doi: 10.1038/srep29506. Sci Rep. 2016. PMID: 27406733 Free PMC article.

8

Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer.

George A, Kaye S, Banerjee S. George A, et al. Nat Rev Clin Oncol. 2017 May;14(5):284-296. doi: 10.1038/nrclinonc.2016.191. Epub 2016 Dec 13. Nat Rev Clin Oncol. 2017. PMID: 27958297 Review.

9

Successful Repatriation of Breast Cancer Surveillance for High-Risk Women to the UK National Health Service Breast Screening Programme.

McVeigh TP, Wiggins J, Ward S, Kemp Z, George AJ. McVeigh TP, et al. Clin Breast Cancer. 2018 Aug;18(4):282-288. doi: 10.1016/j.clbc.2017.10.015. Epub 2017 Oct 28. Clin Breast Cancer. 2018. PMID: 29191429

10

Olaparib for the treatment of relapsed ovarian cancer with a BRCA1/2 mutation.

Stewart J, George A, Banerjee S. Stewart J, et al. Among authors: george a. Expert Rev Anticancer Ther. 2018 Oct;18(10):947-958. doi: 10.1080/14737140.2018.1510323. Epub 2018 Aug 24. Expert Rev Anticancer Ther. 2018. PMID: 30092674 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,955 results

Search Page

Filters